Cargando…

Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveal Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists

Psoriasis is thought to be associated with a reduced life expectancy through systemic inflammation. A comparative, retrospective analysis of neutrophil-to-lymphocyte ratio, a biomarker of systemic inflammation and cardiovascular risk, under 196 treatments with tumour necrosis factor-α and interleuki...

Descripción completa

Detalles Bibliográficos
Autores principales:	HOFFMANN, Jochen H. O., KNOOP, Christian, ENK, Alexander H., HADASCHIK, Eva N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2021
Materias:	Investigative Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425564/ https://www.ncbi.nlm.nih.gov/pubmed/34590148 http://dx.doi.org/10.2340/actadv.v101.271

Ejemplares similares

Evaluation of Psoriasis Area and Severity Index as a Proxy for Biomarkers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles
por: HOFFMANN, Jochen H. O., et al.
Publicado: (2021)

Tumour necrosis factor-alpha and interleukin-8 inhibit neutrophil migration in vitro and in vivo
por: Cunha, F. Q., et al.
Publicado: (1992)

The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids
por: Cecilio, C. A., et al.
Publicado: (1997)

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
por: Hamdi, Haïfa, et al.
Publicado: (2006)

Opioid receptor expression on neutrophils: effect of tumour necrosis factor alpha treatment
por: Schmidt, A, et al.
Publicado: (2007)

Inhibitory effects of bisbenzylisoquinolines on synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha
por: Seow, W. Kim, et al.
Publicado: (1993)

Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha
Publicado: (1992)

Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells.
por: Matossian-Rogers, A., et al.
Publicado: (1989)

Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis
por: Schmeling, H, et al.
Publicado: (2008)

Effect of Exercise Training on Interleukin-6, Tumour Necrosis Factor Alpha and Functional Capacity in Heart Failure
por: Smart, Neil A., et al.
Publicado: (2011)

Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysis
por: SZEBÉNYI, Júlia, et al.
Publicado: (2020)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
por: Fröde, Tânia Silvia, et al.
Publicado: (2002)

Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity.
por: Pullyblank, A. M., et al.
Publicado: (1995)

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
por: Ligo, M., et al.
Publicado: (1989)

Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells
por: Persson, Jenny, et al.
Publicado: (2008)

High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
por: Moon, Dong-Hyuk, et al.
Publicado: (2023)

Elevated interleukin‐6, interleukin‐10 and neutrophil : lymphocyte ratio as identifiers of severe coronavirus disease 2019
por: Godkin, Andrew, et al.
Publicado: (2020)

Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
por: Pirowska, Magdalena, et al.
Publicado: (2019)

Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour
por: Pine, J K, et al.
Publicado: (2015)

Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
por: Miles, D. W., et al.
Publicado: (1992)

Prognostic Utility of Platelet–Lymphocyte Ratio, Neutrophil–Lymphocyte Ratio and Monocyte–Lymphocyte Ratio in Head and Neck Cancers: A Detailed PRISMA Compliant Systematic Review and Meta-Analysis
por: Kumarasamy, Chellan, et al.
Publicado: (2021)

CD23 mediated the induction of pro-inflammatory cytokines Interleukin-1 beta and tumor necrosis factors-alpha in Aspergillus fumigatus keratitis
por: Yan, Hai-Jing, et al.
Publicado: (2021)

Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha co-expression, but little interleukin-22 and interleukin-23R expression
por: Church, Leigh D, et al.
Publicado: (2010)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Tumor Necrosis Factor-Alpha and Interleukin 6 in Human Periapical Lesions
por: Pršo, Ivana Brekalo, et al.
Publicado: (2007)

Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma
por: Hu, Jian, et al.
Publicado: (2018)

Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4.
por: Tsunoda, T., et al.
Publicado: (1996)

The prognostic roles of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in gastrointestinal stromal tumours: a meta-analysis
por: Wei, Zhe-Wei, et al.
Publicado: (2020)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

Influence of Tumour Necrosis Factor Alpha on the Outcome of Ischaemic Postconditioning in the Presence of Obesity and Diabetes
por: Lacerda, Lydia, et al.
Publicado: (2012)

Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.
por: Trentin, L., et al.
Publicado: (1995)

Tumor Necrosis Factor-Alpha and Interleukin-1 Alpha as Predictors of Survival in Peritonitis: A Pilot Study
por: Afuwape, Oludolapo Ola, et al.
Publicado: (2018)

The effect of tumour necrosis factor-α (TNF-α) muteins on human neutrophils in vitro
por: Tchorzewski, H., et al.
Publicado: (1993)

Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma
por: Yoshida, N, et al.
Publicado: (2002)

Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast.
por: Pusztai, L., et al.
Publicado: (1994)

Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology
por: Tse, Brian W. C., et al.
Publicado: (2012)

Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha
por: Stanilov, Noyko, et al.
Publicado: (2014)

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
por: Ruder, Barbara, et al.
Publicado: (2019)

Anti-invasive effects of Celastrus Orbiculatus extract on interleukin-1 beta and tumour necrosis factor-alpha combination-stimulated fibroblast-like synoviocytes
por: Li, Guoqing, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jiohdng0b352mvo7vvdn09n5qu